← Database
Nootropic Peptide

Semax

Third-party suppliers · research use only · not an endorsement. Some links are affiliate links — purchases made through them may earn this site a commission.
Overview

Developed and used clinically in Russia for cognitive and cerebrovascular indications; not approved by FDA/EMA and lacking large Western trials.

How it works

Semax is a short peptide derived from a fragment of the hormone ACTH, but engineered to remove ACTH's hormonal (stress-axis) activity while keeping effects on the brain. It was developed in Russia.

Its proposed mechanism is to raise brain growth factors like BDNF and NGF and to modulate the brain's monoamine systems — the rationale for its use as a neuroprotective and cognitive ('nootropic') agent in cognitive and stroke contexts.

The important caveat is that its clinical evidence is mostly Russian, small, and not replicated in large rigorous Western trials. It is not approved by the FDA or EMA, so its reputation outpaces its proven evidence.

Mechanism · Detailed Analysis
Molecular targetA heptapeptide analogue of ACTH(4-10) stripped of corticotropic activity.
Proposed downstream effectsProposed upregulation of BDNF/NGF and modulation of monoamine systems, giving neuroprotective and pro-cognitive effects.
Evidence & caveatsClinical use and evidence are largely Russian and small; rigorous large-scale Western RCTs are lacking. Not FDA/EMA approved.
Published EvidenceLoading cited studies from PubMed…
Human Data ···

Searching the published record…

Animal ···

Searching the published record…

In Vitro ···

Searching the published record…

Educational aggregation of public literature. Not medical advice and not a recommendation to use any compound. Many compounds here are not approved for human use. Consult a licensed clinician.